SFM
FATE icon

Signet Financial Management’s Fate Therapeutics FATE Stock Holding History

Signet Financial Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-900
Closed -$9K – 1017
2018
Q1 		$9K Buy
+900
New +$8.62K ﹤0.01% 593

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Signet Financial Management's FATE Position: Q2 2018 in Review

Signet Financial Management sold out of Fate Therapeutics (FATE) in Q2 2018, closing a stake of 900 shares — an estimated $9K sold.

Signet Financial Management first reported a position in FATE in Q1 2018 and held it in 1 quarter. The position peaked at $9K in Q1 2018. 103 funds tracked by Wall St. Rank hold FATE as of Q2 2018.

  • Signet Financial Management reported no remaining Fate Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Signet Financial Management sold 900 Fate Therapeutics shares in Q2 2018, an estimated $9K.
  • Signet Financial Management first reported a position in Fate Therapeutics in Q1 2018 and held it in 1 quarter.
  • Signet Financial Management's Fate Therapeutics position peaked at $9K in Q1 2018.
  • 103 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2018.

Based on Signet Financial Management's 13F filing for Q2 2018, filed 10 Aug 2018.